Low-dose DES in the management of CRPC

The value of low-dose diethylstilbestrol (DES) in the management of men with advanced and castration-resistant prostate cancer (CRPC) comes up as a regular topic for review and discussion. Before development of the LHRH agonists, DES was the most commonly used — and much studied — drug for the treatment of advanced (metastatic) prostate cancer. … READ MORE …

Wishful thinking about abiraterone acetate in CRPC

An article from Thursday’s “The Pink Sheet”, posted on the OncologySTAT web site today, is already asking questions about the potential future use of abiraterone acetate in patients with non-metastatic, castration-resistant prostate cancer (CRPC). … READ MORE …

Figitumumab + docetaxel in treatment of CRPC

Figitumumab (also known as CP-751,871) is a fully humanized monoclonal antibody designed to target the insulin-like growth factor type 1 receptor (IGF-IR). Data are now available from a very early-stage trial of figitumumab in combination with docetaxel in the treatment of patients with late-stage solid tumors — including castration-resiatant prostate cancer (CRPC). … READ MORE …

More about ipilimumab, but not in prostate cancer

One of the really “hot” pieces of news from ASCO today was the result of a Phase III clinical trial of ipilimumab in a form of metastatic skin cancer called melanoma. This is (perhaps) very important for prostate cancer patients. … READ MORE …

More data to come at ASCO in June

We commented earlier today on the positive data about tasquinimod that will be presented at the ASCO annual meeting. Negative data will unfortunately be presented on other drugs, but not everything is doom and gloom. … READ MORE …

Tasquinimod in treatment of patients with metastatic CRPC

Looking quickly through the abstracts of presentations on investigational  therapies to be presented at the annual meeting of the American Society for Clinical Oncology (ASCO), starting on June 4 in Chicago, one particular paper stood out — a Phase II trial of tasquinimod. … READ MORE …

Prostate cancer news reports: Saturday, May 1, 2010

Today’s news reports include comments on studies dealing with:

  • A compound panel of markers for predicting risk for prostate cancer
  • Open vs. robot-assisted radical prostatectomy: urologists’ perceptions
  • Clinically relevant quality of life assessment after first-line therapy
  • A compound panel of markers for predicting overall survival of patients with CRPC … READ MORE …